Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
종목 코드 TBPH
회사 이름Theravance Biopharma Inc
상장일May 16, 2014
CEOMr. Rick E. Winningham
직원 수97
유형Ordinary Share
회계 연도 종료May 16
주소Ugland House, South Church Street
도시GEORGE TOWN
증권 거래소NASDAQ Global Market Consolidated
국가Cayman Islands
우편 번호KY1-1104
전화16508086000
웹사이트https://www.theravance.com/
종목 코드 TBPH
상장일May 16, 2014
CEOMr. Rick E. Winningham
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음